- Aventis, Millennium sign $450mm anti-inflammatory drug deal
- Bayer licenses Millennium's discovery technology for $465mm
- Monsanto pays $218mm in genomics pact with Millennium
- Millennium acquires LeukoSite for $585mm
- Millennium to merge BioTherapeutics
- Millennium raises $400mm in private debt offering
- Hoechst, Rhone-Poulenc to merge
- LeukoSite and Kyowa Hakko form chemokine discovery alliance
- LeukoSite and Roche Bioscience work on asthma and allergies
- Astra in 5-year genomic research deal with Millennium
- Millennium acquires Cambridge Discovery Chemistry
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.